Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
Rhea-AI Summary
Silo Pharma (Nasdaq: SILO) acquired assets of Qwikagents.ai and launched a dedicated AI subsidiary to expand into the AI agent market. The firm cites market projections of $47–$53 billion by 2030 and 43–50% annual growth. Silo also plans to submit an IND for SPC-15 to the FDA and advance its PTSD program into Phase 1 after approval.
The move creates a second business line—AI infrastructure—while retaining focus on clinical development.
AI-generated analysis. Not financial advice.
Positive
- Acquired assets of Qwikagents.ai to enter AI agent market
- Formed a dedicated AI subsidiary to operate Qwikagents and future assets
- Cited market projection of $47–$53 billion by 2030 for AI agents
Negative
- Company remains developmental-stage biopharma with limited commercial track record
- Acquisition purchase price not disclosed in the announcement
News Market Reaction – SILO
On the day this news was published, SILO declined 16.85%, reflecting a significant negative market reaction. Argus tracked a peak move of +25.5% during that session. Argus tracked a trough of -32.4% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $10.09M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While SILO was down 9.44%, peers showed mixed but generally positive moves, with names like ARTL up 8.22%. Momentum scanner peers ALZN and ARTL were both moving up, suggesting SILO’s decline diverged from broader biotech strength.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | Policy/PTSD highlight | Positive | +29.3% | Executive order on psychedelics spotlighting SPC-15 PTSD program positioning. |
| Apr 06 | Patent allowance EU | Positive | +49.0% | European patent allowance expanding PTSD-related IP coverage and protection. |
| Feb 23 | Share buyback | Positive | +24.0% | Board-authorized repurchase program of up to $1,000,000 in common stock. |
| Feb 18 | Patent allowance Japan | Positive | -3.2% | Japanese notice of allowance for SPC-15 PTSD patent expanding IP estate. |
| Dec 30 | Clinical development LOI | Positive | +4.7% | LOI with Allucent to support two planned Phase 1 SPC-15 studies. |
Recent SILO headlines have mostly been met with strong positive moves, especially around PTSD IP and the buyback, with only one notable divergence on a positive patent allowance.
Over the last few months, Silo has focused heavily on its PTSD candidate SPC-15 and related IP. European and Japanese patent allowances and a U.S. executive order spotlighting psychedelic therapies coincided with sizable positive moves. A $1,000,000 share repurchase authorization also saw a strong reaction. Today’s AI-focused expansion and Qwikagents acquisition adds a new business line alongside this PTSD trajectory, contrasting with prior, more purely clinical or capital-structure catalysts.
Market Pulse Summary
The stock dropped -16.9% in the session following this news. The decline reflects a negative price response despite a growth-oriented AI expansion layered onto Silo’s PTSD pipeline. Historically, most positive PTSD and capital-returns headlines produced gains, with only one notable divergence on a patent allowance. Recent filings show additional shares registered for warrant exercises and stock issued for the QwikAgents asset, which may raise dilution concerns. The company also remains a developmental-stage issuer, adding execution and funding risk around both AI and clinical plans.
Key Terms
autonomous ai agents technical
ai infrastructure technical
investigational new drug application (ind) regulatory
phase 1 clinical trials medical
first-in-human trial medical
AI-generated analysis. Not financial advice.
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1
SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced a strategic business expansion into AI technology as a second line of business resulting from its recent purchase of the assets of Qwikagents.ai, an AI platform designed to support the deployment of autonomous AI agents.
“We expect that Silo’s diversification into AI infrastructure will enable it to take advantage of opportunities in high-growth, transformative technologies that we believe are driving the current tech economy,” said Eric Weisblum, Chief Executive Officer. “AI agents are increasingly considered a fundamental part of AI infrastructure, and with Qwikagents.ai, we anticipate building a new revenue stream and driving value for our stakeholders.”
According to marketsandmarkets.com, the multi-billion AI agent market is projected to reach
Qwikagents.ai has been designed to provide businesses and individuals with dedicated AI agents capable of executing tasks such as research, content generation, scheduling, and workflow automation. The platform features proprietary smart-routing technology that is expected to optimize cost and performance across multiple AI models, positioning it as a scalable solution in the rapidly growing AI agent market.
“We have recently formed a subsidiary for our new business line that will operate the Qwikagents asset and future AI infrastructure technologies or businesses that we may develop or acquire,” Weisblum added. “At the same time, we remain fully committed to advancing our PTSD program into Phase 1 clinical trials. We are working to submit SPC-15’s investigational new drug application (IND) to the FDA and launch our first-in-human trial after FDA approval.”
About Silo Pharma, Inc.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
(800) 705-0120
investors@silopharma.com
